Yuanyuan Yu (Yusheng Wang)

Publication Activity (10 Years)

Years Active: 2019-2024
Publications (10 Years): 8

Top Topics

Locally Advanced

Metastatic Colorectal Cancer

Signaling Pathway

End Stage Renal Disease

Top Venues

Investigational new drugs

Gastroenterology research and practice

Current cancer drug targets

This page only lists publications with an associated author ORCID identifier.

Publications

Zhuanxia Dong, Zefeng Yang, Jing Ren, Feng Li, Yusheng Wang, Yuanyuan Yu
Envafolimab Inhibits the Growth of Gastric Cancer Cells with Low PD-L1 Expression through the DDX20/NF-κB/TNF-α Signaling Pathway. Current cancer drug targets (2024)
Qianhao Meng, Jian Zhao, Yuanyuan Yu, Ke Wang, Jing Ren, Chang Xu, Yusheng Wang, Guangyu Wang
Survival comparison of first-line treatment regimens in patients with braf-mutated advanced colorectal cancer: a multicenter retrospective study. BMC cancer 23 (1) (2023)
Qianhao Meng, Jian Zhao, Yuanyuan Yu, Ke Wang, Jing Ren, Chang Xu, Yusheng Wang, Guangyu Wang
Survival comparison of first-line treatment regimens in patients with braf-mutated advanced colorectal cancer: a multicenter retrospective study. BMC cancer 23 (1) (2023)
Qianhao Meng, Jian Zhao, Yuanyuan Yu, Ke Wang, Jing Ren, Chang Xu, Yusheng Wang, Guangyu Wang
Survival comparison of first-line treatment regimens in patients with braf-mutated advanced colorectal cancer: a multicenter retrospective study. BMC cancer 23 (1) (2023)
Qianhao Meng, Jian Zhao, Yuanyuan Yu, Ke Wang, Jing Ren, Chang Xu, Yusheng Wang, Guangyu Wang
Survival comparison of first-line treatment regimens in patients with braf-mutated advanced colorectal cancer: a multicenter retrospective study. BMC cancer 23 (1) (2023)
Xuetong Rong, Haiyi Liu, Hongmei Yu, Jian Zhao, Jie Wang, Yuanyuan Yu
Efficacy of apatinib combined with FOLFIRI in the first-line treatment of patients with metastatic colorectal cancer. Investigational new drugs 40 (2) (2022)
Jie Wang, Yanfeng Xi, Jian Zhao, Xuetong Rong, Weidong Lu, Yuanyuan Yu
The Clinicopathological Characteristics and Prognoses of dMMR Gastric Adenocarcinoma Patients. Gastroenterology research and practice 2021 (2021)
Jian Zhao, Junmei Lei, Junyan Yu, Chengyan Zhang, Xuefeng Song, Ninggang Zhang, Yuanyuan Yu, Suxiang Zhang
Clinical efficacy and safety of apatinib combined with S-1 in advanced esophageal squamous cell carcinoma. Investigational new drugs 38 (2) (2019)